Cost effectiveness of treatment for benign prostatic hyperplasia: An economic model for comparison of medical, minimally invasive, and surgical therapy

Journal of Endourology

Volumn 16, Issue 1, 2002, Pages 51-56

  Manyak, Michael J ^a   Ackerman, Stacey J ^b   Blute, Michael L ^c   Rein, Alison L ^b   Buesterien, Kathleen ^b   Sullivan, Erin M ^b   Tanio, Craig P ^d   Strauss, Michael J ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Covance Health Economics and Outcome Services ^*  (United States)

^c MAYO CLINIC   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE;

AGED; ANALYTIC METHOD; CLINICAL FEATURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; HUMAN; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROWAVE IRRADIATION; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; VALIDATION PROCESS;

AGED; COST-BENEFIT ANALYSIS; HUMANS; HYPERTHERMIA, INDUCED; MALE; MODELS, ECONOMIC; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RISK FACTORS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 0036197773     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/089277902753483736     Document Type: Article

References (26)

1. Medical outcomes research and benign prostatic hyperplasia
2. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia: The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate
3. Watchful waiting vs immediate transurethral resection for symptomatic prostatism: The importance of patients' preferences
4. Economic modeling to assess the costs of treatment of finasteride, terasozin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
5. Transurethral prostatectomy: Immediate and postoperative complications - A cooperative study of 13 participating institutions evaluating 3885 patients
6. The costs of prostatectomy for benign prostatic hyperplasia
7. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
8. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
9. Relationships between sponsors and investigators in pharmacoeconomic and clinical research
10. Markov models in medical decision making: A practical guide
11. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia I: Methods
12. U.S. IDE multi-center study results of a new high temperature office based microwave system (T3) for the treatment of BPH
13. Preferential heating using transurethral microwave thermoablation (T3) improves clinical results
14. Durability of results with transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia (BPH) using the Targis (T3) System
15. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus α-blocker treatment of patients with benign prostatic hyperplasia
16. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia II: Results
17. Endoscopic future perspectives: Light as a diagnostic tool
18. Utility assessment in cancer patients: Adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores
19. Transurethral resection of the prostate versus terazosin therapy for benign prostatic hypertrophy: A decision analysis
20. Incorporating risk attitude into Markov-process decision models: Importance for individual decision making
21. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations